Brought to you by 
Aura Biosciences closes $21mm Series B
19 Mar 2015
Executive Summary
Aura Biosciences Inc. (viral nanoparticle technology for cancer drug development) raised $21mm through its Series B round. Advent Life Sciences led and was joined by new investors Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments, along with returning backers LI-COR Biosciences and Henri Termeer (former Genzyme CEO). Advent and Ysios take seats on the company's board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aura Biosciences closes $21mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice